134
Participants
Start Date
October 30, 2020
Primary Completion Date
March 27, 2026
Study Completion Date
March 27, 2026
LXH254
LXH254 will be supplied as tablet for oral use.
LTT462
LTT462 will be supplied as hard gelatin capsule for oral use.
Trametinib
Trametinib will be supplied as film-coated tablet for oral use
Ribociclib
Ribociclib will be supplied in tablets and hard gelatin capsules.
Novartis Investigative Site, Lausanne
Novartis Investigative Site, North Sydney
Novartis Investigative Site, Wilrijk
Novartis Investigative Site, Leuven
Novartis Investigative Site, Wooloongabba
Novartis Investigative Site, Subiaco
Novartis Investigative Site, Zurich
NYU Laura and Isaac Perlmutter Cancer Center, New York
Memorial Sloan Kettering, New York
Novartis Investigative Site, Marseille
University of Pittsburgh Med Center, Pittsburgh
Novartis Investigative Site, Milan
Novartis Investigative Site, Toulouse
H Lee Moffitt Cancer Center and Research Institute, Tampa
Florida Cancer Specialists, Fort Myers
Novartis Investigative Site, Essen
Mayo Clinic Mayo Rochester, Rochester
Mayo Clinic Rochester, Rochester
Novartis Investigative Site, Lille
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Pierre-Bénite
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Paris
Univ of TX MD Anderson Cancer Cntr, Houston
Novartis Investigative Site, Napoli
The Angeles Clinic and Research Institute, Los Angeles
UCSF Medical Center, San Francisco
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Ramat Gan
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Novartis Investigative Site, CABA
Novartis Investigative Site, Dresden
Novartis Investigative Site, Maastricht
Novartis Investigative Site, Oslo
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY